Watching a few other bio's after lackluster earning reports, saw their stocks go down big. Thinking the same with this co so protected myself on downside. Does anybody see any surprise catalyst. Amp litigation still going nowhere, Copax-lit in appeal, No FDA aproval for a second drug. While long term-3 years may have somthing, I can't get excited about the near next qtrs. AS allways IMO.P.S. I see higher expences hit this qtr-on and continuing litigation and R&D expansion.
Sadly, I think the only surprises will be to the downside. As you pointed out, revs should continue to fall, legal expenses should increase and the pipeline is what it is. Suspect the market has priced in a few mil less on the bottom line from last qtr. If worse..suprise